For the fourth consecutive year, Redeye hosts a seminar on ‘Drug development in orphan indications’.

 

Targeting rare diseases come with several advantages in the regulatory, clinical development, and commercial stage. We find some of the biotech success stories on the stock market in this space. A couple of the companies stand on the verge of commercialization.

 

This is a unique opportunity for investors interested in this space. The participating companies will share their equity story, project status, and triggers ahead.

 

Following the presentations, Redeye’s analysts will hold Q&A sessions where questions are open for the audience.